News

CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to ...
Deccan Chronicle7d
Posters Out on Heatstroke, Mango Ripening
Damodar Rajanarsimha requested people to seek immediate medical assistance if symptoms such as fatigue or dizziness occur ...
Safe To Work42m
Mayo Hardware locks in on safety
Mayo Hardware has been the exclusive wholesaler of Master Lock products in Australia for nearly 100 years. Master Lock’s ...
Morningstar3d
CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
Morningstar brands and products Company Portfolio ...
Seeking Alpha3d
CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
The poster is titled ... Phase 1/1b study designed to evaluate the safety and preliminary efficacy of CER-1236 in patients with acute myeloid leukemia that is either relapsed/refractory ...
Bexion Pharmaceuticals, Inc. Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025
Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...
Beyond Compliance: Why Safety Is A Competitive Edge In Food Delivery
In food delivery, speed is the currency. And for too long, safety has been treated as the cost. Companies train drivers on ...
Trump Administration Live Updates: Suit Challenges Immigration Agents’ Access to Schools and Churches
A spokeswoman for the Department of Homeland Security, Tricia McLaughlin, said on Sunday that it was common for parents who ...
Mena FN4d
Cero Therapeutics Holdings, Inc. To Present Poster On Lead Program, CER-1236, At The American Society Of Clinical Oncology (ASCO) 2025 Annual Meeting
The poster is titled,“First-in-human study of ... Phase 1/1b study designed to evaluate the safety and preliminary efficacy of CER-1236 in patients with acute myeloid leukemia that is either ...